These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 23915220

  • 1. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
    Korah R, Healy JM, Kunstman JW, Fonseca AL, Ameri AH, Prasad ML, Carling T.
    Mol Cancer; 2013 Aug 05; 12():87. PubMed ID: 23915220
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, Åkerström G, Westin G, Lifton RP, Björklund P, Carling T.
    Genes Chromosomes Cancer; 2012 Oct 05; 51(10):949-60. PubMed ID: 22733721
    [Abstract] [Full Text] [Related]

  • 3. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
    Cheng JY, Brown TC, Murtha TD, Stenman A, Juhlin CC, Larsson C, Healy JM, Prasad ML, Knoefel WT, Krieg A, Scholl UI, Korah R, Carling T.
    BMC Cancer; 2017 Mar 01; 17(1):164. PubMed ID: 28249601
    [Abstract] [Full Text] [Related]

  • 4. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J, Qi Y, Wang W, Sun F, Wei Q, Su T, Zhou W, Jiang Y, Yuan W, Cai J, Cui B, Ning G.
    Endocrine; 2012 Jun 01; 41(3):479-86. PubMed ID: 22311173
    [Abstract] [Full Text] [Related]

  • 5. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.
    Mohan DR, Lerario AM, Else T, Mukherjee B, Almeida MQ, Vinco M, Rege J, Mariani BMP, Zerbini MCN, Mendonca BB, Latronico AC, Marie SKN, Rainey WE, Giordano TJ, Fragoso MCBV, Hammer GD.
    Clin Cancer Res; 2019 Jun 01; 25(11):3276-3288. PubMed ID: 30770352
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC, Nicolson NG, Korah R, Carling T.
    J Am Coll Surg; 2018 Jun 01; 226(6):988-995. PubMed ID: 29428231
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion.
    Ruggiero C, Doghman-Bouguerra M, Sbiera S, Sbiera I, Parsons M, Ragazzon B, Morin A, Robidel E, Favier J, Bertherat J, Fassnacht M, Lalli E.
    Sci Signal; 2017 Mar 07; 10(469):. PubMed ID: 28270555
    [Abstract] [Full Text] [Related]

  • 10. RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
    Liu-Chittenden Y, Jain M, Gaskins K, Wang S, Merino MJ, Kotian S, Kumar Gara S, Davis S, Zhang L, Kebebew E.
    Oncogene; 2017 Jun 22; 36(25):3541-3552. PubMed ID: 28114280
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer.
    Legendre CR, Demeure MJ, Whitsett TG, Gooden GC, Bussey KJ, Jung S, Waibhav T, Kim S, Salhia B.
    PLoS One; 2016 Jun 22; 11(3):e0150629. PubMed ID: 26963385
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.
    Pereira SS, Máximo V, Coelho R, Batista R, Soares P, Guerreiro SG, Sobrinho-Simões M, Monteiro MP, Pignatelli D.
    J Cell Biochem; 2017 Aug 22; 118(8):2064-2071. PubMed ID: 27886397
    [Abstract] [Full Text] [Related]

  • 16. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B, Sbiera S, Della Casa S, Weigand I, Wild V, Steinhauer S, Fadda G, Kocot A, Bekteshi M, Mambretti EM, Rosenwald A, Pontecorvi A, Fassnacht M, Ronchi CL.
    Oncotarget; 2017 Feb 07; 8(6):9323-9338. PubMed ID: 28030838
    [Abstract] [Full Text] [Related]

  • 17. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
    Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D.
    Clin Cancer Res; 2003 Aug 01; 9(8):2981-4. PubMed ID: 12912945
    [Abstract] [Full Text] [Related]

  • 18. Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.
    Simon DP, Hammer GD.
    Mol Cell Endocrinol; 2012 Mar 31; 351(1):2-11. PubMed ID: 22266195
    [Abstract] [Full Text] [Related]

  • 19. SIRT6 abrogation promotes adrenocortical carcinoma through activation of NF-κB signaling.
    Wu X, Tian H, Xue L, Wang L.
    Mol Cell Biochem; 2019 Aug 31; 458(1-2):1-10. PubMed ID: 30989475
    [Abstract] [Full Text] [Related]

  • 20. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
    Özata DM, Caramuta S, Velázquez-Fernández D, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C, Lui WO.
    Endocr Relat Cancer; 2011 Oct 31; 18(6):643-55. PubMed ID: 21859927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.